jabbrv-ltwa-all.ldf jabbrv-ltwa-en.ldf Background and Aim: The relationship between SGLT-2 (sodium glucose cotransporter-2) inhibitors and atrial fibrillation (AF) recurrence is under investigation. The aim of this study was to investigate the effect of SGLT-2 inhibitors on AF recurrence in patients diagnosed with diabetes mellitus (DM) who underwent Direct Current Cardioversion (DCCV) in our clinic. Method: Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV. Result: During the six-months follow-up period, AF recurrence developed in 24 (40%) patients in SGLT-2 inhibitor group and in 35 (58.3%) of the control group, p= 0.04. In univariate analysis, AF duration, SGLT-2 inhibitor, left atrium diameter, and TAPSE value were significant parameters in terms of AF recurrence. In multivariate analysis, AF duration OR: 4.98; 95% CI (2.39-10.38), p< 0,001 and non-use of SGLT-2 inhibitors OR: 0.35; 95% CI (0.13-0.90), were found to be independent predictors for AF recurrence. Conclusion: AF recurrence ratio is significantly lower in patients using SGLT-2 inhibitors, in six-month follow-up period. AF duration was positive and SGLT-2 inhibitor using was negative independent predictors, for AF recurrence in DM patients.